Table 3.
Treatment tolerability
| Variable | All (n = 90) | AT (n = 24) | RT (n = 23) | CT (n = 20) | AC (n = 23) | P |
|---|---|---|---|---|---|---|
| Lost to follow‐up, no. (%) a | 9 (10) | 1 (4) | 3 (13) | 2 (10) | 3 (13) | 0.73 |
| Attendance, %, mean ± SD a | 79 ± 27 | 86 ± 19 | 77 ± 32 | 75 ± 31 | 76 ± 24 | 0.35 |
| Permanent discontinuation, no. (%) b | 16 (18) | 1 (4) | 5 (22) | 5 (25) | 5 (22) | 0.10 |
| Dose interruption, no. (%) b | 32 (36) | 8 (33) | 10 (44) | 14 (70) | 0 (0) | 0.05 |
| Dose modification, no. (%) b | 52 (58) | 16 (67) | 18 (78) | 18 (90) | 0 (0) | 0.17 |
| Pretreatment dose modification, no. (%) b | 40 (44) | 5 (21) | 18 (78) | 17 (85) | 0 (0) | <0.001 |
| Early session termination, no. (%) b | 25 (28) | 12 (50) | — | 13 (65) | 0 (0) | 0.32 |
AC, attention control; AT, aerobic training; CT, combination training; RT, resistance training; SD, standard deviation.
Lost to follow‐up indicates lack of completion of follow‐up assessments at post‐intervention; attendance indicates ratio of total number of attended to planned treatments; permanent discontinuation indicates permanent discontinuation of treatment prior to Week 16; treatment interruption indicates missing ≥3 consecutive sessions; dose modification indicates ≥10% of sessions requiring modification (reduction/escalation) of intensity or duration; pretreatment dose modification indicates reduction of pretreatment session intensity; early session termination indicates early termination of planned session duration; relative dose intensity indicates the ratio of total ‘completed’ to total ‘planned’ cumulative dose. All variables are collectively counted as one entity in the same patient unless otherwise indicated.
P values obtained from Fisher's exact test or Kruskal–Wallis test for differences across all groups.
P values obtained from Fisher's exact test, Kruskal–Wallis test, or χ 2 test for AT vs. RT vs. CT.